80 4Caracterización de los pacientes con tinnitus y hallazgos audiométricosConocimientos, conductas y toma de decisiones de médicos pediatras sobre hipoacusia infantil en tres hospitales del Servicio de Salud Viña del Mar-Quillota 
Home Page  

  • SciELO

  • Google
  • SciELO
  • Google

Revista de otorrinolaringología y cirugía de cabeza y cuello

 ISSN 0718-4816

TEUBER L., Cristián et al. Prevalence of medication-related osteonecrosis of the jaws in patients treated with intravenous bisphosphonates: an epidemiologic analysis at Centro del Cáncer - Red de Salud UC-CHRISTUS. Rev. Otorrinolaringol. Cir. Cabeza Cuello []. 2020, 80, 4, pp.469-476. ISSN 0718-4816.  http://dx.doi.org/10.4067/S0718-48162020000400469.


Medication-related osteonecrosis of the jaw (MRONJ) is a disease involving exposition of necrotic maxillary and mandibular bone and it's related to antiresorptive and antiangiogenic drugs, with a prevalence that variates from 0,94%-13% in oncologic and osteoporosis patients treated with them.


To determine the prevalence of MRONJ in patients that underwent treatment with intravenous bisphosphonates (IVBP) at Centro del Cancer de la Red de Salud UC-CHRISTUS of Santiago, Chile.

Material and Method:

Data from patients who received intravenous bisphosphonate treatment between March and September 2016 were analyzed, with follow-ups by their treating teams. Data extraction considered gender, age, primary diagnosis, intravenous bisphosphonate used, follow up time, bone metastases and diagnosis of MRONJ.


A sample of 143 patients was obtained with a men:women ratio of 1:2; an average age of 63,2 years, 78% of the patients were treated with zoledronic acid and 22% of the patients with pamidronate. From the total number of patients,1.4% (n = 2) developed MRONJ, both cases had breast cancer as primary diagnosis and in treatment with zoledronic acid, which corresponds to 1.8% of patients being treated with this drug.


Although MRONJ is an infrequent disease, it presents high morbidity and complex management. Prevention and treatment of odontogenic infectious foci in patients before, during and after treatment with IVBP drugs is fundamental to prevent this pathology.

: bisphosphonates; zoledronic acid; pamidronate; osteonecrosis of the jaw.

        ·     ·     · ( pdf )